Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

Panelists discuss how industry-provided patient support services can assist patients receiving bispecific antibodies, particularly in monitoring and follow-up care, and how these services can support patients transitioning from active treatment to maintenance or posttreatment care.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 5:11

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -5:11

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP: 2.Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP: 3.Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

Now Viewing

EP: 4.Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

EP: 5.Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

Video content above is prompted by the following:

• What role would these services play in assisting patients receiving bispecific antibodies, particularly regarding monitoring and follow-up care to ensure optimal outcomes?
• How can industry-provided patient support services help patients transition from active treatment to maintenance or posttreatment care?

Related Videos

Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

Emerging Therapeutic Areas for Bispecific Antibodies

Payer and Reimbursement Considerations for Bispecific Therapies

Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs

Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

Overcoming Access Challenges

Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations